COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Open Label Extension In Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00830180
Recruitment Status : Completed
First Posted : January 27, 2009
Last Update Posted : March 31, 2014
Information provided by (Responsible Party):

Brief Summary:
To evaluate the safety and efficacy of anti-NGF AB in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label therapy.

Condition or disease Intervention/treatment Phase
Neoplasms Bone Metastases Biological: Anti-NGF AB Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Study Start Date : October 2009
Actual Primary Completion Date : February 2013
Actual Study Completion Date : February 2013

Arm Intervention/treatment
Experimental: Anti-NGF AB Biological: Anti-NGF AB
Solution for injection, 10 mg, one injection/8 weeks

Primary Outcome Measures :
  1. Clinical laboratory tests [ Time Frame: 9 months ]
  2. Electrocardiograms [ Time Frame: 9 months ]
  3. Adverse events [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. Brief Pain Inventory [ Time Frame: 9 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Prostate cancer, breast cancer, renal cell carcinoma or multiple myeloma that has been diagnosed as having metastasized to bone;
  • Karnofsky Performance Score ≥40% at Baseline;
  • patients randomized and treated with intravenous study drug in double-blind Study A4091003.

Exclusion Criteria:

  • Patient was withdrawn from Study A4091003 for an adverse event or serious adverse event;
  • Occurrence of any adverse event or condition during Study A4091003 or since termination from that study that, in the opinion of the Investigator, would put the patient at increased safety risk or should exclude the subject from participating in the open-label extension Study A4091029.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00830180

Layout table for location information
United States, California
Pfizer Investigational Site
La Jolla, California, United States, 92037-7651
Pfizer Investigational Site
La Jolla, California, United States, 92093
United States, Louisiana
Pfizer Investigational Site
Shreveport, Louisiana, United States, 71105
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84112-5550
Pfizer Investigational Site
Senftenberg, Austria, A-3541
Bosnia and Herzegovina
Pfizer Investigational Site
Banja Luka, Bosnia and Herzegovina, 78000
Pfizer Investigational Site
Varazdin, Croatia, 42000
Pfizer Investigational Site
Szekesfehervar, Hungary, 8003
Pfizer Investigational Site
Nagpur, Maharashtra, India, 440 010
Pfizer Investigational Site
Nashik, Maharashtra, India, 422 005
Pfizer Investigational Site
Lucknow, Uttar Pradesh, India, 226003
Korea, Republic of
Pfizer Investigational Site
Seoul, Korea, Republic of, 120-752
Pfizer Investigational Site
Seoul, Korea, Republic of, 135-710
Pfizer Investigational Site
Riga, Latvia, LV 1079
Pfizer Investigational Site
Bydgoszcz, Poland, 85-796
Pfizer Investigational Site
Gdansk, Poland, 80-208
Pfizer Investigational Site
Wloclawek, Poland, 87-800
Pfizer Investigational Site
Banska Bystrica, Slovakia, 975 17
Pfizer Investigational Site
Bratislava, Slovakia, 83310
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pfizer Identifier: NCT00830180    
Other Study ID Numbers: A4091029
First Posted: January 27, 2009    Key Record Dates
Last Update Posted: March 31, 2014
Last Verified: March 2014
Keywords provided by Pfizer:
Cancer pain
open-label extension
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes